Vemurafenib drug page Clinical trials

Trials with Vemurafenib

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

17Trials
4Recruiting
17Countries
4.235Planned patients

Showing 1–17 of 17

Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer
Recruiting Phase 2 36 patients NCT06763029

Efficacy and safety of irinotecan liposomes combined with cetuximab + vermofenib in first-line failure of advanced RAS wild /BRAF mutated colorectal cancer, Exploratory analysis of biomarkers (including but not limited to ctDNA, immune mic…

China Feb 2025 – Dec 2026 Interventional
Combined with: Cetuximab
Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer
Recruiting Phase 2 75 patients NCT06603376

Based on the upstream signaling features of BRAFV600E and the bypass feedback mechanisms, considering the pro-apoptotic effects of chemotherapy and the synergistic effects of targeted therapy, previous IMPROVEMENT trial creatively explored…

China Sept 2024 – Dec 2026 Interventional
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Recruiting Phase 3 165 patients NCT06008119

This is a multicenter, randomized, open-label, Phase 3 study

China Oct 2023 – Dec 2026 Interventional
Combined with: Tunlametinib
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Recruiting Phase 2 30 patients NCT05768178

This clinical trial is looking at a combination of drugs called vemurafenib and cobimetinib. Vemurafenib is approved as standard of care for adult patients with unresectable or metastatic melanoma. Cobimetinib is approved as standard of ca…

United Kingdom Mar 2023 – Oct 2029 Interventional
Combined with: Cobimetinib
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Ongoing, not recruiting 1.000 patients NCT05525858

A national, prospective, multi-center, open-label, multi-cohort study comprised of a framework to screen patients for actionable targets and evaluation of molecular profiling guided therapy recommended by MTB based on genomic alterations u…

South Korea Sept 2022 – Mar 2027 Observational
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Ongoing, not recruiting Phase 2 1.377 patients NCT03155620

This phase II Pediatric MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed …

United States, Australia, Canada, Puerto Rico Jul 2017 – Jan 2027 Interventional
Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations
Ongoing, not recruiting Phase 2 216 patients NCT02304809

Patients with metastatic or unresectable locally advanced malignancies harboring BRAF genomic alterations, the biological target of vemurafenib, and who are no more amenable to curative treatment. To explore the efficacy of vemurafenib as…

France Oct 2014 – Oct 2027 Interventional
Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)
Finished Phase 2 NCT05233332

The study consists of the two parts, phase IIa and phase IIb.

China Feb 2022 – Jul 2024 Interventional
Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer
Finished Phase 1 NCT05019534

BRAF mutation exists in about 10-12% of colorectal cancer, among which BRAF V600E mutation is the most common type, which is an important biomarker for predicting the prognosis and precise treatment efficacy of metastatic colorectal cancer…

China Aug 2021 – Dec 2022 Interventional
Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study
Finished 100 patients NCT04831528

This study aimis at detecting the genomic changes of ctDNA in patients of RAS and BRAF wild-type mCRC, who failed after first line treatment containing cetuximab. According to the results of ctDNA detection, individualized second-line targ…

Apr 2021 – Jun 2026 Observational
Combined with: BevacizumabCetuximab
Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer
Finished Phase 1 37 patients NCT04790448

This prospective, multicenter, single arm clinical trial was designed to evaluate the efficacy and safety of Vemurafenib in combination with Irinotecan and Cetuximab in the treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer.

China Jul 2020 – Dec 2021 Interventional
Combined with: CetuximabIrinotecan
Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)
Finished Phase 2 NCT03727763

This clinical trial aims to evaluate the efficacy, safety of FOLFIRI with vemurafenib and cetuximab in Advanced Colorectal Cancer Patients with BRAF V600E mutation.

China Oct 2018 – Dec 2022 Interventional
Combined with: CetuximabIrinotecan
VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer
Finished Phase 3 NCT05540951

In this study, we compared first-line VIC regimen with chemotherapy plus bevacizumab in Chinese patients with initially unresectable BRAF V600E-mutated mCRC. The principal goal was to evaluate the safety of VIC regimen, and to investigate …

China Jun 2018 – Dec 2022 Interventional
A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)
Finished Phase 2 1.044 patients NCT02291289

This randomized, multi-center, active-controlled, open-label, parallel-group study will investigate the efficacy and safety of biomarker-driven maintenance treatment for first-line mCRC. Participants with mCRC are eligible for entry and ca…

Argentina, Belgium, Bosnia and Herzegovina, Brazil and 6 more Apr 2015 – Mar 2021 Interventional
S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
Finished Phase 2 106 patients NCT02164916

This randomized phase II trial studies how well irinotecan hydrochloride and cetuximab with or without vemurafenib works in treating patients with colorectal cancer that has spread to nearby tissue or lymph nodes, that has spread to other …

United States Nov 2014 – Nov 2020 Interventional
Combined with: Cetuximab
Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
Finished Phase 1 33 patients NCT01787500

This phase I trial studies the side effects and best dose of vemurafenib when given together with cetuximab and irinotecan hydrochloride in treating patients with solid tumors that have spread to other parts of the body or cannot be remove…

United States Feb 2013 – Mar 2026 Interventional
Combined with: Cetuximab
Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer
Finished Phase 1 16 patients NCT01791309

The purpose of this study is to test a new drug combination consisting of two drugs, vemurafenib (also known as ZelborafTM) and panitumumab (also known as VectibixTM). This treatment is being tested in a subgroup of patients with colorecta…

United States Jan 2013 – Mar 2015 Interventional

Where the recruiting trials are